S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
Log in
NYSE:PEN

Penumbra Competitors

$284.43
-0.27 (-0.09 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$276.95
Now: $284.43
$289.28
50-Day Range
$197.71
MA: $253.43
$288.94
52-Week Range
$121.80
Now: $284.43
$314.22
Volume471,671 shs
Average Volume607,197 shs
Market Capitalization$10.33 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.43

Competitors

Penumbra (NYSE:PEN) Vs. BAX, DXCM, RMD, TFX, PODD, and NVCR

Should you be buying PEN stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Penumbra, including Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Insulet (PODD), and NovoCure (NVCR).

Baxter International (NYSE:BAX) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Analyst Ratings

This is a summary of current ratings and target prices for Baxter International and Penumbra, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Baxter International061002.63
Penumbra02402.67

Baxter International presently has a consensus price target of $92.2667, indicating a potential upside of 18.76%. Penumbra has a consensus price target of $279.00, indicating a potential downside of 1.91%. Given Baxter International's higher probable upside, equities analysts plainly believe Baxter International is more favorable than Penumbra.

Volatility and Risk

Baxter International has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Profitability

This table compares Baxter International and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Baxter International7.90%20.81%8.78%
Penumbra-1.79%-0.12%-0.09%

Valuation and Earnings

This table compares Baxter International and Penumbra's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baxter International$11.36 billion3.45$1.00 billion$3.3123.47
Penumbra$547.41 million18.87$48.46 million$0.98290.23

Baxter International has higher revenue and earnings than Penumbra. Baxter International is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.9% of Baxter International shares are owned by institutional investors. Comparatively, 88.2% of Penumbra shares are owned by institutional investors. 0.1% of Baxter International shares are owned by company insiders. Comparatively, 8.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Baxter International beats Penumbra on 10 of the 14 factors compared between the two stocks.

DexCom (NASDAQ:DXCM) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Profitability

This table compares DexCom and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DexCom12.69%27.29%10.45%
Penumbra-1.79%-0.12%-0.09%

Valuation and Earnings

This table compares DexCom and Penumbra's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$1.48 billion25.92$101.10 million$1.84216.18
Penumbra$547.41 million18.87$48.46 million$0.98290.23

DexCom has higher revenue and earnings than Penumbra. DexCom is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

DexCom has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for DexCom and Penumbra, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DexCom121402.76
Penumbra02402.67

DexCom presently has a consensus price target of $430.3750, indicating a potential upside of 8.19%. Penumbra has a consensus price target of $279.00, indicating a potential downside of 1.91%. Given DexCom's stronger consensus rating and higher probable upside, equities analysts plainly believe DexCom is more favorable than Penumbra.

Institutional and Insider Ownership

94.1% of DexCom shares are owned by institutional investors. Comparatively, 88.2% of Penumbra shares are owned by institutional investors. 0.7% of DexCom shares are owned by company insiders. Comparatively, 8.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

DexCom beats Penumbra on 13 of the 14 factors compared between the two stocks.

ResMed (NYSE:RMD) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares ResMed and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ResMed22.45%30.64%16.43%
Penumbra-1.79%-0.12%-0.09%

Valuation & Earnings

This table compares ResMed and Penumbra's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$2.96 billion9.49$621.67 million$4.7640.50
Penumbra$547.41 million18.87$48.46 million$0.98290.23

ResMed has higher revenue and earnings than Penumbra. ResMed is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ResMed has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ResMed and Penumbra, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ResMed05402.44
Penumbra02402.67

ResMed currently has a consensus target price of $189.40, indicating a potential downside of 1.75%. Penumbra has a consensus target price of $279.00, indicating a potential downside of 1.91%. Given ResMed's higher probable upside, analysts clearly believe ResMed is more favorable than Penumbra.

Insider & Institutional Ownership

68.6% of ResMed shares are owned by institutional investors. Comparatively, 88.2% of Penumbra shares are owned by institutional investors. 1.3% of ResMed shares are owned by insiders. Comparatively, 8.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

ResMed beats Penumbra on 8 of the 13 factors compared between the two stocks.

Teleflex (NYSE:TFX) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares Teleflex and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teleflex14.66%16.33%7.66%
Penumbra-1.79%-0.12%-0.09%

Valuation & Earnings

This table compares Teleflex and Penumbra's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teleflex$2.60 billion7.14$461.47 million$11.1535.71
Penumbra$547.41 million18.87$48.46 million$0.98290.23

Teleflex has higher revenue and earnings than Penumbra. Teleflex is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Teleflex has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Teleflex and Penumbra, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teleflex00913.10
Penumbra02402.67

Teleflex currently has a consensus target price of $433.60, indicating a potential upside of 8.91%. Penumbra has a consensus target price of $279.00, indicating a potential downside of 1.91%. Given Teleflex's stronger consensus rating and higher probable upside, analysts clearly believe Teleflex is more favorable than Penumbra.

Insider & Institutional Ownership

89.8% of Teleflex shares are owned by institutional investors. Comparatively, 88.2% of Penumbra shares are owned by institutional investors. 2.2% of Teleflex shares are owned by insiders. Comparatively, 8.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Teleflex beats Penumbra on 13 of the 15 factors compared between the two stocks.

Insulet (NASDAQ:PODD) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Risk and Volatility

Insulet has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Insulet and Penumbra, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insulet113602.25
Penumbra02402.67

Insulet currently has a consensus target price of $246.50, indicating a potential downside of 4.86%. Penumbra has a consensus target price of $279.00, indicating a potential downside of 1.91%. Given Penumbra's stronger consensus rating and higher probable upside, analysts clearly believe Penumbra is more favorable than Insulet.

Profitability

This table compares Insulet and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insulet3.33%8.94%2.07%
Penumbra-1.79%-0.12%-0.09%

Insider & Institutional Ownership

88.2% of Penumbra shares are owned by institutional investors. 1.1% of Insulet shares are owned by insiders. Comparatively, 8.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Insulet and Penumbra's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$738.20 million23.14$11.60 million$0.191,363.68
Penumbra$547.41 million18.87$48.46 million$0.98290.23

Penumbra has lower revenue, but higher earnings than Insulet. Penumbra is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Summary

Insulet beats Penumbra on 8 of the 14 factors compared between the two stocks.

Penumbra (NYSE:PEN) and NovoCure (NASDAQ:NVCR) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Penumbra has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Penumbra and NovoCure, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Penumbra02402.67
NovoCure14402.33

Penumbra currently has a consensus target price of $279.00, indicating a potential downside of 1.91%. NovoCure has a consensus target price of $126.00, indicating a potential downside of 15.49%. Given Penumbra's stronger consensus rating and higher possible upside, equities analysts plainly believe Penumbra is more favorable than NovoCure.

Profitability

This table compares Penumbra and NovoCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Penumbra-1.79%-0.12%-0.09%
NovoCure4.26%7.40%3.94%

Insider and Institutional Ownership

88.2% of Penumbra shares are held by institutional investors. Comparatively, 71.1% of NovoCure shares are held by institutional investors. 8.9% of Penumbra shares are held by insiders. Comparatively, 5.1% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Penumbra and NovoCure's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$547.41 million18.87$48.46 million$0.98290.23
NovoCure$351.32 million43.20$-7,230,000.00($0.07)-2,130.00

Penumbra has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Summary

Penumbra beats NovoCure on 7 of the 13 factors compared between the two stocks.


Penumbra Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Baxter International logo
BAX
Baxter International
2.3$77.69-1.2%$39.24 billion$11.36 billion44.14
DexCom logo
DXCM
DexCom
1.7$397.78-0.6%$38.26 billion$1.48 billion164.37Insider Selling
ResMed logo
RMD
ResMed
1.4$192.78-1.1%$28.05 billion$2.96 billion41.37
Teleflex logo
TFX
Teleflex
2.0$398.12-1.1%$18.54 billion$2.60 billion51.24Earnings Announcement
Dividend Announcement
Analyst Report
Insulet logo
PODD
Insulet
1.3$259.10-1.4%$17.08 billion$738.20 million588.88Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
NovoCure logo
NVCR
NovoCure
1.5$149.10-0.1%$15.18 billion$351.32 million784.78Earnings Announcement
High Trading Volume
News Coverage
Gap Up
Abiomed logo
ABMD
Abiomed
1.5$324.55-1.3%$14.68 billion$840.88 million71.33
Hill-Rom logo
HRC
Hill-Rom
2.2$106.67-0.6%$7.08 billion$2.88 billion32.13
Haemonetics logo
HAE
Haemonetics
1.6$126.50-2.1%$6.43 billion$988.48 million61.11
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.4$232.79-2.8%$6.27 billion$82.05 million-100.34Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Globus Medical logo
GMED
Globus Medical
1.6$62.50-0.8%$6.17 billion$785.37 million67.93Analyst Report
Gap Down
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.4$95.99-1.0%$5.85 billion$362.30 million-118.50Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$68.34-1.3%$5.77 billion$1.52 billion102.00Analyst Report
Nevro logo
NVRO
Nevro
1.2$165.18-1.2%$5.69 billion$390.26 million-60.73Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inari Medical logo
NARI
Inari Medical
0.8$104.60-0.2%$5.10 billionN/A0.00Insider Selling
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.6$160.90-8.2%$4.65 billion$214.55 million-84.24Earnings Announcement
Analyst Downgrade
ICU Medical logo
ICUI
ICU Medical
1.5$207.50-5.2%$4.35 billion$1.27 billion54.89Earnings Announcement
Analyst Report
News Coverage
Glaukos logo
GKOS
Glaukos
0.9$94.56-2.6%$4.25 billion$236.98 million-57.31Earnings Announcement
News Coverage
SWAV
ShockWave Medical
1.4$116.76-0.2%$4.00 billion$42.93 million-57.80Analyst Report
Insider Selling
News Coverage
Cantel Medical logo
CMD
Cantel Medical
1.3$74.28-1.2%$3.14 billion$1.02 billion88.43News Coverage
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.7$55.72-1.6%$3.10 billion$994.85 million-105.13Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
NuVasive logo
NUVA
NuVasive
1.3$60.33-3.0%$3.09 billion$1.17 billion-274.23Earnings Announcement
AtriCure logo
ATRC
AtriCure
1.5$65.27-0.8%$2.94 billion$230.81 million-56.76Earnings Announcement
Analyst Report
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$11.10-3.5%$2.07 billion$4.11 million-8.16Upcoming Earnings
LUNG
Pulmonx
0.7$56.83-5.0%$2.03 billion$32.60 million0.00Upcoming Earnings
High Trading Volume
Gap Down
AXNX
Axonics Modulation Technologies
1.5$50.31-1.0%$2.00 billion$13.82 million-25.67Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
SILK
Silk Road Medical
1.1$54.77-0.3%$1.86 billion$63.35 million-44.89Upcoming Earnings
Insider Selling
News Coverage
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.5$41.30-0.2%$1.66 billion$236.54 million-62.57
Luminex logo
LMNX
Luminex
1.8$32.52-1.4%$1.51 billion$334.64 million83.39
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.4$19.55-3.8%$1.40 billion$88.02 million-47.68Earnings Announcement
Gap Up
Alphatec logo
ATEC
Alphatec
0.8$16.05-1.4%$1.26 billion$113.43 million-14.59Upcoming Earnings
Atrion logo
ATRI
Atrion
1.1$624.90-2.4%$1.16 billion$155.07 million35.21
MDXG
MiMedx Group
0.0$9.91-1.6%$1.10 billion$299.26 million-10.54News Coverage
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.3$54.46-0.3%$1.06 billion$72.55 million-37.82Upcoming Earnings
Analyst Downgrade
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.39-9.6%$1.05 billion$117.23 million55.26Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Down
Cerus logo
CERS
Cerus
1.5$6.14-5.0%$1.03 billion$74.65 million-15.74Earnings Announcement
News Coverage
Gap Up
SIBN
SI-BONE
1.2$31.39-0.9%$1.02 billion$67.30 million-19.62Gap Down
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.4$50.82-1.5%$991.40 million$189.49 million-112.93Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
CryoLife logo
CRY
CryoLife
1.8$25.25-0.0%$981.14 million$276.22 million-66.45
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$46.51-0.2%$899.22 million$459.95 million38.76
AngioDynamics logo
ANGO
AngioDynamics
1.4$20.95-2.4%$795.35 million$264.16 million-4.69
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.60-0.8%$760.37 million$154.60 million-46.09Upcoming Earnings
Intersect ENT logo
XENT
Intersect ENT
1.2$22.81-1.5%$746.32 million$109.14 million-11.94
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$29.25-0.9%$741.25 millionN/A-12.89Earnings Announcement
Surmodics logo
SRDX
Surmodics
1.5$52.15-0.9%$717.38 million$94.86 million651.88Unusual Options Activity
News Coverage
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.25-5.2%$708.36 million$123.86 million70.85Upcoming Earnings
VAPO
Vapotherm
1.5$24.30-4.7%$623.56 million$48.10 million-11.57Analyst Report
AFIB
Acutus Medical
1.5$20.76-0.7%$578.08 million$2.84 million0.00Upcoming Earnings
SeaSpine logo
SPNE
SeaSpine
1.3$18.92-3.0%$522.82 million$159.08 million-11.33Upcoming Earnings
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.7$36.70-1.9%$521.69 million$114.51 million-78.09Upcoming Earnings
News Coverage
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.